Physician profile
Robert A Denton
NPI 1568491439
$849.81
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $676 · 2020: $154 · 2021: $4.67 · 2022: $14.38.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $300.73 | 2019-2022 | |
| Glaxosmithkline, LLC. | $210.94 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $83.36 | 2019-2020 | |
| United Therapeutics Corporation | $59.41 | 2019-2021 | |
| Mylan Specialty L.P. | $48.98 | 2019-2020 | |
| Actelion Pharmaceuticals US, INC. | $43.60 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.86 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.66 | 2020 | |
| Philips North America LLC | $13.74 | 2019 | |
| Novartis Pharmaceuticals Corporation | $13.52 | 2019 | |
| Shire North American Group INC | $12.60 | 2019 | |
| Circassia INC. | $12.08 | 2019 | |
| Merck Sharp & Dohme LLC | $11.33 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Denton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.